This study provides the proof of concept that available drugs targeting mitochondrial ribogenesis or mitoribosome function can improve the anticancer effects of emerging new drugs capable of selectively targeting nucleolar Pol I rRNA synthesis in cancer and, in particular, MYC-driven cancer of different histotypes due to concomitant MYC deregulation of both nucleolar and mitochondrial rRNA synthesis and ribogenesis processes. The gene discussed is MYC; the disease is cancer.